根据卵巢癌和脑转移患者的 BRCA 状态、聚（ADP-核糖）聚合酶抑制剂 (PARPi) 的给药和手术来评估疾病特征和生存率。这是卵巢癌和脑转移患者的单中心回顾性队列2000 年至 2021 年间治疗的转移瘤。通过回顾性审查病历收集数据，并根据以下因素进行分析：（1）BRCA 突变； (2)脑转移前后的PARPi； (3)脑转移手术。对85例卵巢癌脑转移且已知BRCA状态的患者(31例BRCA突变型(BRCAm)，54例BRCA野生型(BRCAwt))进行了分析。 22 名患者在脑转移诊断前（11 名 BRCAm，11 名 BRCAwt）和 12 名患者（8 名 BRCAm，4 名 BRCAwt）在诊断脑转移后接受了 PARPi。先前接受过 PARPi 治疗的患者超过 1 年后发生脑转移。 BRCAm 组的生存期更长（脑转移后中位生存期：BRCAm 23 个月 vs BRCAwt 8 个月，p=0.0015）。根据对脑转移后未接受 PARPi 的人群进行 BRCA 状态分析，未发现差异（脑转移后中位生存期：BRCAm 8 个月与 BRCAwt 8 个月，p=0.31）。在 BRCAm 组中，既往接受过 PARPi 治疗的患者的生存期较差（脑转移后生存中位数：接受 PARPi 治疗前 7 个月 vs 接受过 PARPi 治疗前 24 个月，p=0.003）。如果在脑转移后给予 PARPi，总体生存率会提高（脑转移后中位生存期：PARPi 后 46 个月 vs 无 PARPi 后 8 个月，p=0.00038）。预后似乎更好（脑转移后中位生存期：手术 13 个月与非手术 8 个月，p=0.036）。多变量分析显示，三个变量与延长生存期显着相关：BRCA 突变、多模式治疗和≤1 种既往化疗方案。BRCA 突变可能会影响脑转移的发生并带来更好的结果。在多模式治疗中，即使在颅外疾病的情况下，手术似乎也会影响生存。应考虑使用 PARPi，因为如果在脑转移后施用，它似乎可以延长生存期。© IGCS 和 ESGO 2024。不得商业重复使用。请参阅权利和权限。英国医学杂志出版。

To evaluate disease characteristics and survival according to BRCA status, administration of poly-(ADP-ribose) polymerase inhibitors (PARPi), and surgery in patients with ovarian cancer and brain metastases.This is a monocentric retrospective cohort of patients with ovarian cancer and brain metastases treated between 2000 and 2021. Data were collected by a retrospective review of medical records and analyzed according to: (1) BRCA mutation; (2) PARPi before and after brain metastases; (3) surgery for brain metastases.Eighty-five patients with ovarian cancer and brain metastasis and known BRCA status (31 BRCA mutated (BRCAm), 54 BRCA wild-type (BRCAwt)) were analyzed. Twenty-two patients had received PARPi before brain metastases diagnosis (11 BRCAm, 11 BRCAwt) and 12 after (8 BRCAm, 4 BRCAwt). Brain metastases occurred >1 year later in patients who had received previous PARPi. Survival was longer in the BRCAm group (median post-brain metastasis survival: BRCAm 23 months vs BRCAwt 8 months, p=0.0015). No differences were found based on BRCA status analyzing the population who did not receive PARPi after brain metastasis (median post-brain metastasis survival: BRCAm 8 months vs BRCAwt 8 months, p=0.31). In the BRCAm group, survival was worse in patients who had received previous PARPi (median post-brain metastasis survival: PARPi before, 7 months vs no-PARPi before, 24 months, p=0.003). If PARPi was administered after brain metastases, survival of the overall population improved (median post-brain metastasis survival: PARPi after, 46 months vs no-PARPi after, 8 months, p=0.00038).In cases of surgery for brain metastases, the prognosis seemed better (median post-brain metastasis survival: surgery 13 months vs no-surgery 8 months, p=0.036). Three variables were significantly associated with prolonged survival at multivariate analysis: BRCA mutation, multimodal treatment, and ≤1 previous chemotherapy line.BRCA mutations might impact brain metastasis occurrence and lead to better outcomes. In a multimodal treatment, surgery seems to affect survival even in cases of extracranial disease. PARPi use should be considered as it seems to prolong survival if administered after brain metastasis.© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.